Skip to main content
OpenTrials

Clinical trial condition

Hemorrhagic Disorders

Explore clinical trials studying Hemorrhagic Disorders. Study availability and eligibility vary by location and protocol.

4,580 public trials 828 recruiting studies
Refine in advanced search Browse all conditions

Hemorrhagic Disorders trial results

Active, Not Recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Research Site Santa Barbara, California, United States
  • Research Site Aurora, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Minneapolis, Minnesota, United States
View all 38 locations
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

NCT07150091

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site São Paulo, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
View Trial Details
Active, Not Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Yuma Regional Medical Center Yuma, Arizona, United States
  • University of Colorado Anschutz Aurora, Colorado, United States
  • NorthShore University Health System Evanston, Illinois, United States
  • Boston Medical Center Boston, Massachusetts, United States
View all 77 locations
View Trial Details
Active, Not Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Yuma Regional Medical Center Yuma, Arizona, United States
  • Community Cancer Institute Clovis, California, United States
  • Compassionate Care Res Group Inc Fountain Valley, California, United States
  • University of Colorado Anschutz Aurora, Colorado, United States
View all 111 locations
View Trial Details
Active, Not Recruiting

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

NCT04998786

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHR Annecy, France
  • CH de la cote basque Bayonne, France
  • CHRU Hopital Haut Lévêque Bordeaux, France
  • CHU Caen, France
View all 21 locations
View Trial Details
Active, Not Recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

NCT06297655

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Fuyang Hospital Affiliated to Anhui Medical University Fuyang, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • The Second Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality, China
  • The First Hospital of Lanzhou University Lanzhou, Gansu, China
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fort Myers, Florida, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Kansas City, Missouri, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Nagoya, Aichi-ken, Japan
  • GSK Investigational Site Kamogawa, Chiba, Japan
  • GSK Investigational Site Kashiwa, Chiba, Japan
  • GSK Investigational Site Matsuyama, Ehime, Japan
View all 13 locations
View Trial Details

Related conditions